Global PD-1 and PD-L1 Inhibitors Market Growth 2022-2028
As the global economy mends, the 2021 growth of PD-1 and PD-L1 Inhibitors will have significant change from previous year. According to our latest study, the global PD-1 and PD-L1 Inhibitors market size is USD million in 2022 from USD 38690 million in 2021, with a change of % between 2021 and 2022. The global PD-1 and PD-L1 Inhibitors market size will reach USD 146540 million in 2028, growing at a CAGR of 21.0% over the analysis period.
The United States PD-1 and PD-L1 Inhibitors market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global PD-1 and PD-L1 Inhibitors market, reaching US$ million by the year 2028. As for the Europe PD-1 and PD-L1 Inhibitors landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main PD-1 and PD-L1 Inhibitors players cover Merck, Bristol-Myers Squibb, Roche, and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PD-L1 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
PD-1 Inhibitors
PD-L1 Inhibitors
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Solid Tumors
Blood-related Tumors
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PD-1 and PD-L1 Inhibitors Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Country/Region, 2017, 2022 & 2028
2.2 PD-1 and PD-L1 Inhibitors Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.3 PD-1 and PD-L1 Inhibitors Sales by Type
2.3.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)
2.3.2 Global PD-1 and PD-L1 Inhibitors Revenue and Market Share by Type (2017-2022)
2.3.3 Global PD-1 and PD-L1 Inhibitors Sale Price by Type (2017-2022)
2.4 PD-1 and PD-L1 Inhibitors Segment by Application
2.4.1 Solid Tumors
2.4.2 Blood-related Tumors
2.5 PD-1 and PD-L1 Inhibitors Sales by Application
2.5.1 Global PD-1 and PD-L1 Inhibitors Sale Market Share by Application (2017-2022)
2.5.2 Global PD-1 and PD-L1 Inhibitors Revenue and Market Share by Application (2017-2022)
2.5.3 Global PD-1 and PD-L1 Inhibitors Sale Price by Application (2017-2022)
3 Global PD-1 and PD-L1 Inhibitors by Company
3.1 Global PD-1 and PD-L1 Inhibitors Breakdown Data by Company
3.1.1 Global PD-1 and PD-L1 Inhibitors Annual Sales by Company (2020-2022)
3.1.2 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2020-2022)
3.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue by Company (2020-2022)
3.2.1 Global PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2022)
3.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2020-2022)
3.3 Global PD-1 and PD-L1 Inhibitors Sale Price by Company
3.4 Key Manufacturers PD-1 and PD-L1 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 and PD-L1 Inhibitors Product Location Distribution
3.4.2 Players PD-1 and PD-L1 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region
4.1 World Historic PD-1 and PD-L1 Inhibitors Market Size by Geographic Region (2017-2022)
4.1.1 Global PD-1 and PD-L1 Inhibitors Annual Sales by Geographic Region (2017-2022)
4.1.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue by Geographic Region
4.2 World Historic PD-1 and PD-L1 Inhibitors Market Size by Country/Region (2017-2022)
4.2.1 Global PD-1 and PD-L1 Inhibitors Annual Sales by Country/Region (2017-2022)
4.2.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue by Country/Region
4.3 Americas PD-1 and PD-L1 Inhibitors Sales Growth
4.4 APAC PD-1 and PD-L1 Inhibitors Sales Growth
4.5 Europe PD-1 and PD-L1 Inhibitors Sales Growth
4.6 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Growth
5 Americas
5.1 Americas PD-1 and PD-L1 Inhibitors Sales by Country
5.1.1 Americas PD-1 and PD-L1 Inhibitors Sales by Country (2017-2022)
5.1.2 Americas PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2022)
5.2 Americas PD-1 and PD-L1 Inhibitors Sales by Type
5.3 Americas PD-1 and PD-L1 Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PD-L1 Inhibitors Sales by Region
6.1.1 APAC PD-1 and PD-L1 Inhibitors Sales by Region (2017-2022)
6.1.2 APAC PD-1 and PD-L1 Inhibitors Revenue by Region (2017-2022)
6.2 APAC PD-1 and PD-L1 Inhibitors Sales by Type
6.3 APAC PD-1 and PD-L1 Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe PD-1 and PD-L1 Inhibitors by Country
7.1.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2017-2022)
7.1.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2022)
7.2 Europe PD-1 and PD-L1 Inhibitors Sales by Type
7.3 Europe PD-1 and PD-L1 Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PD-1 and PD-L1 Inhibitors by Country
8.1.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Country (2017-2022)
8.1.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2022)
8.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Type
8.3 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Inhibitors
10.3 Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
10.4 Industry Chain Structure of PD-1 and PD-L1 Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 and PD-L1 Inhibitors Distributors
11.3 PD-1 and PD-L1 Inhibitors Customer
12 World Forecast Review for PD-1 and PD-L1 Inhibitors by Geographic Region
12.1 Global PD-1 and PD-L1 Inhibitors Market Size Forecast by Region
12.1.1 Global PD-1 and PD-L1 Inhibitors Forecast by Region (2023-2028)
12.1.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1 and PD-L1 Inhibitors Forecast by Type
12.7 Global PD-1 and PD-L1 Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck PD-1 and PD-L1 Inhibitors Product Offered
13.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Offered
13.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche PD-1 and PD-L1 Inhibitors Product Offered
13.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca PD-1 and PD-L1 Inhibitors Product Offered
13.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Ono Pharmaceutical
13.5.1 Ono Pharmaceutical Company Information
13.5.2 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Offered
13.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Ono Pharmaceutical Main Business Overview
13.5.5 Ono Pharmaceutical Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron PD-1 and PD-L1 Inhibitors Product Offered
13.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent PD-1 and PD-L1 Inhibitors Product Offered
13.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Information
13.8.2 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Offered
13.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Hengrui Medicine Main Business Overview
13.8.5 Hengrui Medicine Latest Developments
13.9 Junshi Biosciences
13.9.1 Junshi Biosciences Company Information
13.9.2 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Offered
13.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Junshi Biosciences Main Business Overview
13.9.5 Junshi Biosciences Latest Developments
13.10 Merck KGaA
13.10.1 Merck KGaA Company Information
13.10.2 Merck KGaA PD-1 and PD-L1 Inhibitors Product Offered
13.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Merck KGaA Main Business Overview
13.10.5 Merck KGaA Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. PD-1 and PD-L1 Inhibitors Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. PD-1 and PD-L1 Inhibitors Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of PD-1 Inhibitors
Table 4. Major Players of PD-L1 Inhibitors
Table 5. Global PD-1 and PD-L1 Inhibitors Sales by Type (2017-2022) & (L)
Table 6. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)
Table 7. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2017-2022) & ($ million)
Table 8. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2017-2022)
Table 9. Global PD-1 and PD-L1 Inhibitors Sale Price by Type (2017-2022) & (USD/ml)
Table 10. Global PD-1 and PD-L1 Inhibitors Sales by Application (2017-2022) & (L)
Table 11. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)
Table 12. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2017-2022)
Table 13. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2017-2022)
Table 14. Global PD-1 and PD-L1 Inhibitors Sale Price by Application (2017-2022) & (USD/ml)
Table 15. Global PD-1 and PD-L1 Inhibitors Sales by Company (2020-2022) & (L)
Table 16. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2020-2022)
Table 17. Global PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2022) ($ Millions)
Table 18. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2020-2022)
Table 19. Global PD-1 and PD-L1 Inhibitors Sale Price by Company (2020-2022) & (USD/ml)
Table 20. Key Manufacturers PD-1 and PD-L1 Inhibitors Producing Area Distribution and Sales Area
Table 21. Players PD-1 and PD-L1 Inhibitors Products Offered
Table 22. PD-1 and PD-L1 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global PD-1 and PD-L1 Inhibitors Sales by Geographic Region (2017-2022) & (L)
Table 26. Global PD-1 and PD-L1 Inhibitors Sales Market Share Geographic Region (2017-2022)
Table 27. Global PD-1 and PD-L1 Inhibitors Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global PD-1 and PD-L1 Inhibitors Sales by Country/Region (2017-2022) & (L)
Table 30. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Country/Region (2017-2022)
Table 31. Global PD-1 and PD-L1 Inhibitors Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas PD-1 and PD-L1 Inhibitors Sales by Country (2017-2022) & (L)
Table 34. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2017-2022)
Table 35. Americas PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2017-2022)
Table 37. Americas PD-1 and PD-L1 Inhibitors Sales by Type (2017-2022) & (L)
Table 38. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)
Table 39. Americas PD-1 and PD-L1 Inhibitors Sales by Application (2017-2022) & (L)
Table 40. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)
Table 41. APAC PD-1 and PD-L1 Inhibitors Sales by Region (2017-2022) & (L)
Table 42. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2017-2022)
Table 43. APAC PD-1 and PD-L1 Inhibitors Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2017-2022)
Table 45. APAC PD-1 and PD-L1 Inhibitors Sales by Type (2017-2022) & (L)
Table 46. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)
Table 47. APAC PD-1 and PD-L1 Inhibitors Sales by Application (2017-2022) & (L)
Table 48. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)
Table 49. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2017-2022) & (L)
Table 50. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2017-2022)
Table 51. Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2017-2022)
Table 53. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2017-2022) & (L)
Table 54. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)
Table 55. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2017-2022) & (L)
Table 56. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Country (2017-2022) & (L)
Table 58. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Type (2017-2022) & (L)
Table 62. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Application (2017-2022) & (L)
Table 64. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of PD-1 and PD-L1 Inhibitors
Table 66. Key Market Challenges & Risks of PD-1 and PD-L1 Inhibitors
Table 67. Key Industry Trends of PD-1 and PD-L1 Inhibitors
Table 68. PD-1 and PD-L1 Inhibitors Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. PD-1 and PD-L1 Inhibitors Distributors List
Table 71. PD-1 and PD-L1 Inhibitors Customer List
Table 72. Global PD-1 and PD-L1 Inhibitors Sales Forecast by Region (2023-2028) & (L)
Table 73. Global PD-1 and PD-L1 Inhibitors Sales Market Forecast by Region
Table 74. Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global PD-1 and PD-L1 Inhibitors Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2023-2028) & (L)
Table 77. Americas PD-1 and PD-L1 Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC PD-1 and PD-L1 Inhibitors Sales Forecast by Region (2023-2028) & (L)
Table 79. APAC PD-1 and PD-L1 Inhibitors Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2023-2028) & (L)
Table 81. Europe PD-1 and PD-L1 Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2023-2028) & (L)
Table 83. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global PD-1 and PD-L1 Inhibitors Sales Forecast by Type (2023-2028) & (L)
Table 85. Global PD-1 and PD-L1 Inhibitors Sales Market Share Forecast by Type (2023-2028)
Table 86. Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global PD-1 and PD-L1 Inhibitors Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global PD-1 and PD-L1 Inhibitors Sales Forecast by Application (2023-2028) & (L)
Table 89. Global PD-1 and PD-L1 Inhibitors Sales Market Share Forecast by Application (2023-2028)
Table 90. Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global PD-1 and PD-L1 Inhibitors Revenue Market Share Forecast by Application (2023-2028)
Table 92. Merck Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck PD-1 and PD-L1 Inhibitors Product Offered
Table 94. Merck PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 95. Merck Main Business
Table 96. Merck Latest Developments
Table 97. Bristol-Myers Squibb Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 98. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Offered
Table 99. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 100. Bristol-Myers Squibb Main Business
Table 101. Bristol-Myers Squibb Latest Developments
Table 102. Roche Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 103. Roche PD-1 and PD-L1 Inhibitors Product Offered
Table 104. Roche PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 105. Roche Main Business
Table 106. Roche Latest Developments
Table 107. AstraZeneca Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 108. AstraZeneca PD-1 and PD-L1 Inhibitors Product Offered
Table 109. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 110. AstraZeneca Main Business
Table 111. AstraZeneca Latest Developments
Table 112. Ono Pharmaceutical Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 113. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Offered
Table 114. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 115. Ono Pharmaceutical Main Business
Table 116. Ono Pharmaceutical Latest Developments
Table 117. Regeneron Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 118. Regeneron PD-1 and PD-L1 Inhibitors Product Offered
Table 119. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 120. Regeneron Main Business
Table 121. Regeneron Latest Developments
Table 122. Innovent Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 123. Innovent PD-1 and PD-L1 Inhibitors Product Offered
Table 124. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 125. Innovent Main Business
Table 126. Innovent Latest Developments
Table 127. Hengrui Medicine Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 128. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Offered
Table 129. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 130. Hengrui Medicine Main Business
Table 131. Hengrui Medicine Latest Developments
Table 132. Junshi Biosciences Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 133. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Offered
Table 134. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 135. Junshi Biosciences Main Business
Table 136. Junshi Biosciences Latest Developments
Table 137. Merck KGaA Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 138. Merck KGaA PD-1 and PD-L1 Inhibitors Product Offered
Table 139. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2020-2022)
Table 140. Merck KGaA Main Business
Table 141. Merck KGaA Latest Developments
List of Figures
Figure 1. Picture of PD-1 and PD-L1 Inhibitors
Figure 2. PD-1 and PD-L1 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 and PD-L1 Inhibitors Sales Growth Rate 2017-2028 (L)
Figure 7. Global PD-1 and PD-L1 Inhibitors Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. PD-1 and PD-L1 Inhibitors Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of PD-1 Inhibitors
Figure 10. Product Picture of PD-L1 Inhibitors
Figure 11. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type in 2021
Figure 12. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2017-2022)
Figure 13. PD-1 and PD-L1 Inhibitors Consumed in Solid Tumors
Figure 14. Global PD-1 and PD-L1 Inhibitors Market: Solid Tumors (2017-2022) & (L)
Figure 15. PD-1 and PD-L1 Inhibitors Consumed in Blood-related Tumors
Figure 16. Global PD-1 and PD-L1 Inhibitors Market: Blood-related Tumors (2017-2022) & (L)
Figure 17. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)
Figure 18. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application in 2021
Figure 19. PD-1 and PD-L1 Inhibitors Revenue Market by Company in 2021 ($ Million)
Figure 20. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Company in 2021
Figure 21. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Geographic Region in 2021
Figure 23. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2017-2022)
Figure 24. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Country/Region in 2021
Figure 25. Americas PD-1 and PD-L1 Inhibitors Sales 2017-2022 (L)
Figure 26. Americas PD-1 and PD-L1 Inhibitors Revenue 2017-2022 ($ Millions)
Figure 27. APAC PD-1 and PD-L1 Inhibitors Sales 2017-2022 (L)
Figure 28. APAC PD-1 and PD-L1 Inhibitors Revenue 2017-2022 ($ Millions)
Figure 29. Europe PD-1 and PD-L1 Inhibitors Sales 2017-2022 (L)
Figure 30. Europe PD-1 and PD-L1 Inhibitors Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales 2017-2022 (L)
Figure 32. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue 2017-2022 ($ Millions)
Figure 33. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Country in 2021
Figure 34. Americas PD-1 and PD-L1 Inhibitors Revenue Market Share by Country in 2021
Figure 35. United States PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Region in 2021
Figure 40. APAC PD-1 and PD-L1 Inhibitors Revenue Market Share by Regions in 2021
Figure 41. China PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 45. India PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Country in 2021
Figure 48. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Country in 2021
Figure 49. Germany PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 50. France PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Country in 2021
Figure 55. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Country in 2021
Figure 56. Egypt PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country PD-1 and PD-L1 Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Inhibitors in 2021
Figure 62. Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
Figure 63. Industry Chain Structure of PD-1 and PD-L1 Inhibitors
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
